---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-003639"
form_type: "8-K"
ticker: "DWTX"
cik: "0001818844"
company_name: "Dogwood Therapeutics, Inc."
filed_at: "2023-03-14T23:59:59+00:00"
generated_at: "2026-06-18T03:47:07.644218+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Virios posts FY2022 net loss $12.2M; cash $7.0M; FDA meeting on IMC-1 Phase 3 in March

## Summary
- Net loss Q4 2022 $2.0M ($0.11/share) vs $4.5M in Q4 2021; FY2022 net loss $12.2M ($1.11) vs $16.0M in FY2021.
- Cash $7.0M at Dec 31, 2022; expects funding through mid-2024 for current ops but needs additional funds for IMC-1 FM trials.
- End-of-Phase 2 meeting with FDA in March 2023 to discuss IMC-1 progression into Phase 3 development.
- Patient enrollment complete for exploratory Long-COVID study; top-line results expected mid-2023.
- R&D expenses decreased to $1.3M in Q4 2022 vs $2.9M in Q4 2021; FY2022 R&D $8.1M vs $10.8M.

## SEC filing metadata
- accession: 0001558370-23-003639
- form_type: 8-K
- ticker: DWTX
- cik: 0001818844
- company_name: Dogwood Therapeutics, Inc.
- filed_at: 2023-03-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818844/000155837023003639/0001558370-23-003639-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818844/000155837023003639/tmb-20230314x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-003639
- JSON: https://secwatch.observer/filing/0001558370-23-003639.json
- Plain text: https://secwatch.observer/filing/0001558370-23-003639.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.